Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models

Head and neck squamous cell carcinoma (HNSCC) currently only has one FDA-approved cancer intrinsic targeted therapy, the epidermal growth factor receptor (EGFR) inhibitor cetuximab, to which only approximately 10% of tumors are sensitive. In order to extend therapy options, we subjected patient-deri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Xiaoming, Barling, Ashley, Lesch, Aletha, Tyner, Jeffrey W., Choonoo, Gabrielle, Zheng, Christina, Jeng, Sophia, West, Toni M., Clayburgh, Daniel, Courtneidge, Sara A., McWeeney, Shannon K., Kulesz-Martin, Molly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300392/
https://www.ncbi.nlm.nih.gov/pubmed/29856687
http://dx.doi.org/10.1080/15384047.2018.1451285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300392/
https://www.ncbi.nlm.nih.gov/pubmed/29856687
http://dx.doi.org/10.1080/15384047.2018.1451285

Ejemplares similares